Physician profile
Robert T Chasse
NPI 1619967049
$12,654.69
in general payments reported to CMS, 2019-2025
47 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,340 · 2020: $950 · 2021: $1,943 · 2022: $1,799 · 2023: $2,037 · 2024: $2,321 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,016 · Travel and Lodging: $417 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,016.38 |
| Travel and Lodging | $416.97 |
| Education | $188.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,842.77 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,331.93 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pulmonx Corporation | $1,107.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,062.08 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mallinckrodt Hospital Products INC. | $734.80 | 2020-2025 | Acthar, Terlivaz |
| Actelion Pharmaceuticals US, INC. | $717.39 | 2019-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $647.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $471.62 | 2021-2025 | Dupixent |
| Noah Medical Corporation | $416.97 | 2024 | Galaxy |
| Takeda Pharmaceuticals U.S.A., INC. | $414.57 | 2020-2025 | Glassia |
| United Therapeutics Corporation | $340.16 | 2019-2025 | Tyvaso, Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $307.67 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $288.49 | 2019-2024 | |
| Genentech USA, INC. | $277.26 | 2019-2025 | Xolair |
| Insmed, INC. | $217.77 | 2019-2024 | Arikayce |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $216.52 | 2023-2025 | Tezspire |
| Mylan Specialty L.P. | $215.23 | 2019-2021 | |
| Philips North America LLC | $192.72 | 2019-2025 | Vest Therapy Und |
| Grifols USA, LLC | $183.43 | 2019-2024 | Prolastin-C Liquid |
| Baxter Healthcare | $142.58 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Fluid Systems - Premix Drugs |
| Harmony Biosciences LLC | $134.55 | 2020-2025 | Wakix |
| Gilead Sciences, INC. | $120.86 | 2021-2023 | Veklury |
| Electromed, INC. | $115.80 | 2022-2025 | Smartvest |
| Sunovion Pharmaceuticals INC. | $101.14 | 2019 | |
| Vifor Pharma, INC. | $94.23 | 2024-2025 | Zemaira |
| Sanofi-Aventis U.S. LLC | $88.99 | 2023 | |
| Inspire Medical Systems, INC. | $88.76 | 2025 | Inspire |
| Verona Pharma, INC. | $78.91 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $71.05 | 2021-2022 | |
| Boston Scientific Corporation | $68.37 | 2023-2024 | Ekosonic, Exalt Model D |
| Advanced Respiratory, INC | $64.76 | 2019-2020 | |
| Abbvie INC. | $60.81 | 2024-2025 | |
| Pharming Healthcare, INC. | $60.16 | 2023 | Ruconest |
| Pfizer INC. | $46.88 | 2022-2024 | |
| Shire North American Group INC | $45.94 | 2019 | |
| Allergan, INC. | $38.24 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $34.73 | 2021 | |
| Ani Pharmaceuticals, INC. | $34.01 | 2023 | Purified Cortrophin Gel |
| Resmed Corp | $33.45 | 2019-2023 | |
| Getinge USA Sales, LLC | $28.18 | 2024 | Cardiohelp |
| Merck Sharp & Dohme LLC | $27.27 | 2025 | Keytruda |
| Lilly USA, LLC | $21.06 | 2025 | Zepbound |
| Shionogi INC | $20.72 | 2022 | |
| Partner Therapeutics, INC. | $18.00 | 2021 | |
| Mallinckrodt Enterprises LLC | $14.25 | 2019 | |
| Eisai INC. | $14.13 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chasse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.